Edition:
United States

Cempra Inc (CEMP.O)

CEMP.O on Nasdaq

3.85USD
25 May 2017
Change (% chg)

$0.05 (+1.32%)
Prev Close
$3.80
Open
$3.85
Day's High
$3.90
Day's Low
$3.75
Volume
592,267
Avg. Vol
1,442,547
52-wk High
$26.95
52-wk Low
$2.55

Select another date:

Fri, Apr 28 2017

BRIEF-Cempra Q1 loss per share $0.44

* Cempra reports first quarter 2017 financial results and provides corporate update

BRIEF-Cempra retains Morgan Stanley to lead review of strategic business options

* Cempra retains Morgan Stanley to lead review of strategic business options

BRIEF-Cempra Q4 loss per share $0.60

* Cempra provides corporate update and reports fourth quarter and full year 2016 financial results

Cempra's bacterial skin infection drug clears study, shares surge

Cempra Inc said on Friday that its experimental oral drug to treat acute bacterial skin infections cleared a late-stage study, bringing the antibiotic developer one step closer to getting its first drug to market.

UPDATE 2-Cempra's bacterial skin infection drug clears study, shares surge

* Cempra shares rise 38 pct, set for best day ever (Adds details, analyst comment)

BRIEF-Cempra’s fusidic acid achieves primary endpoint in phase 3 study of Absssi

* Cempra’s fusidic acid achieves primary endpoint in phase 3 study of Absssi

REFILE-Cempra's bacterial skin infection drug succeeds in key study

Feb 24 Cempra Inc said on Friday that its experimental drug to treat acute bacterial skin infections met the main goal of a late-stage study, sending the company's shares surging 41 percent in premarket trading.

FDA rejects Cempra's antibiotic for pneumonia, shares sink

Cempra Inc said on Thursday the U.S. Food and Drug Administration had rejected its antibiotic for community-acquired bacterial pneumonia (CABP), citing inadequate data on the drug's impact on the liver and manufacturing issues.

Select another date:

More From Around the Web